Nevada Coalition for Psychedelic Medicines

Nevada Coalition for Psychedelic Medicines Saving Lives | Revolutionizing Mental Health The Nevada Coalition for Psychedelic Medicines is dedicated to healing through the use of psychedelic substances.

We strive to increase access to and understanding of these substances as potential therapies for mental health and well-being and to eliminate the stigma and criminalization associated with their use. Through collaboration, advocacy, and education, we aim to improve the health and lives of individuals in our state and nation.

Ushering in this new era of psychedelic research will take time, so Dalton and Cotter are readying Nevadans for that fut...
04/30/2026

Ushering in this new era of psychedelic research will take time, so Dalton and Cotter are readying Nevadans for that future. They are gearing up for next year’s legislative session and expanding outreach to inform state leaders and community members about the issue.

“Psychedelic therapy, where you’re working with a medical professional that’s trained in working with psychedelics, and you work through your issues … I came out the other side with an emotional range that was greater than I had ever had, and so, it was like the lights got turned back on for my emotions,” said Dalton, who co-founded the Nevada Coalition for Psychedelic Medicines.

Kate Cotter, co-founder with Dalton of the NCPM and its sibling organization Sierra Psychedelic Society, said psychedelic-assisted treatments can be “very safe” when used with proper guidance and screening, citing studies from Stanford, the University of New Mexico and Johns Hopkins University. She and Dalton also point to Dustin and Rochelle Hines, associate professors of neuroscience in UNLV’s psychology department, who they said “are constantly doing studies on various psychedelics.”

“Nevada has been ahead of the curve on this issue, and I’m proud to have led SJR 10 to push for expanded research, federal rescheduling and legal pathways for supervised treatment,” state Sen. Rochelle Nguyen, D-Las Vegas, one of the bill’s sponsors, said in a statement.

Nevada would be a good testing ground for future treatments, considering its high population of veterans and those living with substance use disorders, Dalton and Cotter said. In 2022, Nevada was home to more than 205,000 veterans, and the National Alliance on Mental Illness said 600,000 adults in Nevada had a mental health condition as of March 2025.

Link to the full article:
https://lasvegassun.com/news/2026/apr/29/once-illegal-now-hopeful-nevada-advocates-eye-trum/

The April 18th White House executive order on psychedelics is best understood not as a legalization measure, but a polic...
04/29/2026

The April 18th White House executive order on psychedelics is best understood not as a legalization measure, but a policy shift accelerating treatment development. The Administration framed it explicitly as a mental health initiative - “Removing barriers to psychedelic drugs” - for serious mental illnesses like PTSD, depression, and addiction

In practical terms, the Executive Order should quickly expand access to investigational psychedelics through Right-to-Try pathways, particularly for patients with serious or treatment-resistant illnesses without access to clinical trials. However, such access does not substitute for the evidentiary standards required by the FDA.

The EO signals a new priority to NIH, which will influence funding allocation and may affect reviewers’ mindsets. Anchoring in the VA system provides an important real-world data infrastructure, large, centralized patient populations, and built-in longitudinal follow-up. This VA partnership could be the big game-changer, materially accelerating evidence generation.

Check out the full article here:
https://www.psychologytoday.com/us/blog/addiction-outlook/202604/the-new-executive-order-eo-on-psychedelics-what-comes-next

Join us THIS THURSDAY, APRIL 30th for a special screening of In Waves and War, followed by a live panel discussion explo...
04/28/2026

Join us THIS THURSDAY, APRIL 30th for a special screening of In Waves and War, followed by a live panel discussion exploring trauma, healing, and the evolving conversation around innovative approaches to mental health.

In Waves and War is a powerful documentary following three Navy SEAL veterans navigating the invisible wounds of war. Through deeply personal stories and cutting-edge research, the film illuminates the profound toll of trauma while exploring emerging therapeutic approaches that are reshaping how we understand healing and recovery.

Following the screening, guests are invited to stay for a thoughtful panel discussion featuring voices from neuroscience, veteran leadership, medicine, public policy, and law enforcement advocacy.

THIS EVENT IS FREE AND OPEN TO THE PUBLIC!

RENO EVENT DETAILS:

Date: April 30th
Time: 6:00 PM – 9:00 PM (Doors open at 6 PM, film starts 6:30 PM)
Location: Truckee Meadow Community College
Sierra Building | Room 108
Address: 7000 Dandini Blvd, Reno, NV 89512
Link in bio to reserve your free spot!

With panelists:
Dr. Sarah Henry, Neuropsychologist
Jon Dalton, Retired SEAL, VETS Grant Recipient
Asm. Natha Anderson (D)
Asm. Alexis Hansen (R)

Moderated by Kate Cotter, ED, NCPM

In addition, the agency is allowing an early phase clinical study of noribogaine hydrochloride to move forward following...
04/27/2026

In addition, the agency is allowing an early phase clinical study of noribogaine hydrochloride to move forward following an Investigational New Drug (IND) submission.

The sponsor is investigating noribogaine as a potential treatment for alcohol use disorder, a condition with high relapse rates and limited treatment options.

This is the first instance in which the FDA has allowed a clinical study in the U.S. of a derivative of ibogaine, a psychoactive indole alkaloid derived from the African Tabernanthe iboga shrub.  

This decision allows the company developing the novel drug, DemeRx NB, to begin a phase I clinical study of the drug in a closely monitored clinical setting in the United States.  

Dive into the full article here:
https://www.fda.gov/news-events/press-announcements/fda-accelerates-action-treatments-serious-mental-illness-following-executive-order

The legislation—titled the Veterans Health Administration Novel Therapeutics Preparedness Act—is being led by Sen. Tim S...
04/23/2026

The legislation—titled the Veterans Health Administration Novel Therapeutics Preparedness Act—is being led by Sen. Tim Sheehy (R-MT) and is cosponsored by Sens. Tammy Duckworth (D-IL), Ruben Gallego (D-AZ) and John Boozman (R-AR).

The Senate Veterans’ Affairs Committee will take up the psychedelics bill, along with 24 other pieces of legislation, on Wednesday.

Check out the full article:
https://www.marijuanamoment.net/senate-committee-schedules-hearing-on-bill-to-support-psychedelics-research-and-treatment-for-veterans/

As most of us have already learned, this past weekend, President Donald J. Trump signed a groundbreaking Executive Order...
04/22/2026

As most of us have already learned, this past weekend, President Donald J. Trump signed a groundbreaking Executive Order accelerating research and improving access to psychedelic drugs as promising treatments for serious mental illnesses.

The order prioritizes breakthroughs that could offer new hope to millions of Americans - particularly our nation’s brave veterans, who continue to face disproportionately high rates of su***de and often don’t respond to conventional therapies.

The press release highlights statements of support from:
- Americans for Ibogaine CEO W. Bryan Hubbard
- Americans for Ibogaine Chairman and Former Texas Gov. Rick Perry
- American Legion National Commander Dan K. Wiley
- (Our very now) Nevada Coalition for Psychedelic Medicines President Jon Dalton
And many more!

Follow the link below to dive into the full press release, or by following the link in our bio
https://www.whitehouse.gov/releases/2026/04/president-trumps-landmark-order-advances-breakthrough-mental-health-treatments-delivering-new-hope-to-veterans/

As most of us have already learned, this past weekend, President Donald J. Trump signed a groundbreaking Executive Order...
04/21/2026

As most of us have already learned, this past weekend, President Donald J. Trump signed a groundbreaking Executive Order accelerating research and improving access to psychedelic drugs as promising treatments for serious mental illnesses.

The order prioritizes breakthroughs that could offer new hope to millions of Americans - particularly our nation’s brave veterans, who continue to face disproportionately high rates of su***de and often don’t respond to conventional therapies.

Yesterday’s press release showcased countless veterans’ organizations, medical professionals, patient advocates, and industry leaders who welcomed the historic action. The press release highlights support from:
- Americans for Ibogaine CEO W. Bryan Hubbard
- Americans for Ibogaine Chairman and Former Texas Gov. Rick Perry
- American Legion National Commander Dan K. Wiley
- (Our very now) Nevada Coalition for Psychedelic Medicines President Jon Dalton
- Veterans Exploring Treatment Solutions Co-Founder and CEO Marcus Capone
- Veterans Exploring Treatment Solutions Co-Founder and CEO Amber Capone
- Beond Co-Founder and CEO Tom Feegel
And many more!

Follow the link below to dive into the full press release, or by following the link in our bio
https://www.whitehouse.gov/releases/2026/04/president-trumps-landmark-order-advances-breakthrough-mental-health-treatments-delivering-new-hope-to-veterans/

ACCELERATING TREATMENTS TO BENEFIT ALL AMERICANS, ESPECIALLY OUR BRAVE MILITARY VETERANS: America has long struggled to ...
04/20/2026

ACCELERATING TREATMENTS TO BENEFIT ALL AMERICANS, ESPECIALLY OUR BRAVE MILITARY VETERANS: America has long struggled to address the burden of su***de and serious mental illness rates in America, with our veterans often suffering in greater measure. President Trump is working to bring about new options for patients whose conditions have not responded to existing treatments.

Check out the latest fact sheet from the White House by following the link below:
https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-is-accelerating-medical-treatments-for-serious-mental-illness/

NEVADA –  The Nevada Coalition for Psychedelic Medicines (NCPM) today applauded President Trump’s signing of a landmark ...
04/18/2026

NEVADA –  The Nevada Coalition for Psychedelic Medicines (NCPM) today applauded President Trump’s signing of a landmark executive order directing federal agencies to accelerate research into the therapeutic benefits of psychedelic compounds, including psilocybin, M**A, L*D, and ibogaine. The executive order, signed Saturday in the Oval Office, represents the most significant federal action on psychedelic medicine in over fifty years and directly aligns with the mission NCPM has pursued at both the state and federal level.

Scroll through this post to dive into our full press release. For all of the details regarding our upcoming In Waves & War screening events, follow the link(s) in our bio.

“Millions of Americans living with depression, PTSD, addiction and other conditions do not respond to existing treatment...
04/18/2026

“Millions of Americans living with depression, PTSD, addiction and other conditions do not respond to existing treatments. We owe it to our warfighters and veterans to turn over every stone to alleviate the emotional and mental health blowback from their deployments.

I᥇oᧁainꫀ treatment is reported to alleviate a spectrum of mood and anxiety symptoms and is associated with self-reported improvements in cognitive functioning in individuals with substance-use disorders. During treatment, i᥇oᧁainꫀ allows the evocation and reprocessing of traumatic memories and occasions therapeutic and meaningful visions of spiritual and autobiographical content, which are of central relevance in addressing PTSD-related psychological content.”



Check out the full article, here:
https://www.foxnews.com/politics/trump-signs-executive-order-directing-fda-review-psychedelics-designated-breakthrough-therapy-drugs

I᥇oᧁainꫀ, a naturally occurring compound from a shrub native to Africa, is used to treat depression, anxiety, addiction,...
04/17/2026

I᥇oᧁainꫀ, a naturally occurring compound from a shrub native to Africa, is used to treat depression, anxiety, addiction, post-traumatic stress disorder and brain trauma. 

Researchers say i᥇oᧁainꫀ could eventually fill a gap in addiction treatment, particularly for opioid dependence, but more large-scale clinical trials are needed before it can be considered safe or effective for any condition.

The scientific evidence behind the drug so far consists mostly of small observational studies and open-label trials. Only one double-blind, placebo-controlled randomized clinical trial has been completed. More advanced trials are just now getting underway.

Check out the full article here:
https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/

“Current antidepressants often take weeks to produce clinical improvement, which represents a major limitation, especial...
04/16/2026

“Current antidepressants often take weeks to produce clinical improvement, which represents a major limitation, especially for patients with severe symptoms. Rapid-acting antidepressants such as S-𝓀𝑒tam𝒾𝓃𝑒 have shown promising results, but their clinical use is limited by adverse effects and potential for abuse,” said study author Elaine Gavioli, a professor of pharmacology at the Federal University of Rio Grande do Norte.

“As N,N-dimethyltryptamine (DℳT) has recently gained attention as a potential rapid-acting antidepressant, preclinical evidence comparing its effects with established rapid-acting treatments remains limited. So, we investigated and compared the antidepressant- and anxiolytic-like effects of DℳT and S-𝓀𝑒tam𝒾𝓃𝑒 in a preclinical model, aiming to better understand how emerging compounds might perform relative to an already established rapid-acting treatment.”

Check out the full article here:
https://www.psypost.org/researchers-find-dmt-provides-longer-lasting-antidepressant-effects-than-s-ketamine-in-animal-models/

Address

415 S Beretania St
Honolulu, HI
96813

Alerts

Be the first to know and let us send you an email when Nevada Coalition for Psychedelic Medicines posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Nevada Coalition for Psychedelic Medicines:

Share